Clinical Trial Update: Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers [Phase 1]

View source ↗

Summary

This is a completed Phase 1 safety study of navitoclax (ABT-263) in combination with rituximab for CD20-positive lymphoid malignancies, including chronic lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Navitoclax (navitoclax)
• Rituximab (rituximab)

Snippet

Sponsor: AbbVie | Conditions: CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia | Phase 1 | Status: COMPLETED